J Gastroenterol Hepatol Endosc | Volume 6, Issue 2 | Research Article | Open Access
Raga Priya* and Mary Lilly
Department of Pathology, Sree Balaji Medical College and Hospital, India
*Correspondance to: Raga Priya
Fulltext PDFAim: To evaluate the association and prognostic significance of P53 in gastric neoplasms with tumour site and its macroscopic appearance.
Methods: A total of 48 cases of endoscopic gastric biopsies and surgically resected specimens that include both pre-malignant and malignant neoplasms were collected. The following inclusion and exclusion criteria were adopted.
Inclusion Criteria: All gastric adenocarcinoma cases reported in both endoscopic biopsies as well as resected specimens, irrespective of age and sex were included for the study.
Exclusion Criteria: Non-neoplastic lesions and benign tumors of stomach, Malignancies other than adenocarcinoma and Gastrectomies performed for reasons other than gastric tumors were excluded from the study.
Results: GCs had a peak incidence in the age group of 51 to 60 years. The youngest age of presentation of gastric cancer was at 37 years in this study. 30 (62%) cases were reported in males and 18 (38%) cases were reported in females with Male:Female ratio accounting to 1.6:1. 25 (52.08%) cases involved the pyloro-antrum, 12 (25%) involved body, 5 (10.42%) involved eso-cardia, 3 (6.25%) cases involved fundus and 3 (6.25%) cases involved pan-gastric region. Ulcero-proliferative type (35%) was the most common gross appearance followed by ulcerative type (29%). P53 positivity was observed in 84% of tumors in pyloro-antrum, 83.2% of tumors in body, 40% of tumors in esocardia. 33.1% of tumors in fundus and 66.7% in pan-gastric tumors. The association with respect to site was found to be statistically significant with increased expression seen in tumors of pyloroantrum.
Among various gross types, P53 positivity was noted in 8 cases (57.8%) of ulcerative type, 9 cases (75%) of Nodular type, 15 cases (88.2%) of Ulcero-proliferative type and 3 cases (60%) of proliferative type. P53 expression showed statistically significant association with tumour location but not with macroscopic appearance.
Conclusion: Identifying expression of P53 in GC could be helpful in categorizing patients eligible for targeted therapy. Patients at high risk of recurrence and poor survival can also be identified. A larger sample size and follow-up of these patients for 5 more years could throw more light on role of P53 mutation as long-term prognostic indicator.
Gastric carcinoma; P53; Prognostic indicator
Priya R, Lilly M. Histomorphological Study of Gastric Carcinoma and Correlation with P53 Immunohistochemistry. J Gastroenterol
Hepatol Endosc. 2021; 6(2): 1095..